Reuters logo
BRIEF-Ultragenyx announces top-line results from phase 3 study of ace-ER in GNE Myopathy
2017年8月22日 / 晚上8点25分 / 1 个月前

BRIEF-Ultragenyx announces top-line results from phase 3 study of ace-ER in GNE Myopathy

Aug 22 (Reuters) - Ultragenyx Pharmaceutical Inc

* Ultragenyx announces top-line results from phase 3 study of ace-ER in GNE Myopathy

* Ultragenyx Pharmaceutical Inc - ‍study also did not meet its key secondary endpoints​

* Ultragenyx - ‍adverse events were generally balanced between ace-ER and placebo and safety was consistent with previously released ace-ER data​

* ‍study did not achieve its primary endpoint​

* Says ‍outcome does not affect co’s overall strategy​

* ‍overall in study, ace-ER was well tolerated​

* Ultragenyx Pharmaceutical Inc - ‍company plans to terminate ace-ER​ development program based on study results

* Ultragenyx Pharmaceutical - in study, ‍there were 3 serious adverse events including 2 on ace-ER, 1 on placebo, none of which were considered treatment related​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below